KDOAM-25
Based on 9 publication(s) in Google Scholar
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2230731-99-2
- 分子式: C15H25N5O2
- 分子量:307.39
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 KDOAM-25
More- Nat Cell Biol. 2024 Feb;26(2):263-277. [Abstract]
- Sci Adv. 2025 Jun 6;11(23):eadu2695. [Abstract]
- Clin Transl Med. 2024 Jun;14(6):e1692. [Abstract]
- Oncol Rep. 2026 Apr;55(4):79. [Abstract]
- Clin Exp Med. 2025 Nov 25;26(1):33. [Abstract]
- Cancer Res Commun. 2026 Mar 1;6(3):616-629. [Abstract]
- bioRxiv. 2024 October 03.
- Research Square Preprint. 2023 Dec 2.
- University of Gothenburg. 2023 Jun 27.
生物活性
IC50: 71 nM (KDM5A), 19 nM (KDM5B), 69 nM (KDM5C), 69 nM (KDM5D)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MM1.S | EC50 |
>50 μM
Compound: 15
|
Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability
Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability
|
[PMID: 34555614] |
| MM1.S | IC50 |
30 μM
Compound: 11d
|
Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth
Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth
|
[PMID: 32883639] |
KDOAM-25 inhibits most potently KDM5B with an IC50 of ∼50 μM and the other KDM5 family members at concentrations above 100 μM. KDOAM-25 shows no cellular activity on any of the other tested JmjC family members[1].
KDOAM-25 is able to reduce the viability of MM1S cells with an IC50 of ∼30 μM after a delay of 5-7 days[1].
KDOAM-25 treatment results in a G1 cell-cycle arrest with an increased proportion of MM1S in G1 and a decrease of the proportion of cells in G2 without an increase in the proportion of cells in the apoptotic sub-G1 phase[1].
KDOAM-25 (50 μM) increases with approximately twice as much H3K4me3 in in multiple myeloma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 2230731-99-2
-
分子量 307.39
-
分子式 C15H25N5O2
-
SMILES
NC(C1=CC=NC(CNCC(N(CC)CCN(C)C)=O)=C1)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Cell Biol
Single-cell multi-omics profiling of human preimplantation embryos identifies cytoskeletal defects during embryonic arrest. [Abstract]2024 Feb;26(2):263-277. PMID: 38238450 -
Sci Adv
Determining sex differences in aortic valve myofibroblast responses to drug combinations identified using a digital medicine platform. [Abstract]2025 Jun 6;11(23):eadu2695. PMID: 40479052 -
Clin Transl Med
Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer. [Abstract]2024 Jun;14(6):e1692. PMID: 38804602 -
Oncol Rep
2026 Apr;55(4):79. PMID: 41789643 -
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164 -
Cancer Res Commun
Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. [Abstract]2026 Mar 1;6(3):616-629. PMID: 41747217 -
-
-
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
KDOAM-25 関連分類
HY-102047 関連分類
Powered by Bioz